Abstract
Igeneon, under license from Protein Design Labs, is developing IGN-311, an intravenous humanized monoclonal antibody against the Lewis Y carbohydrate antigen, as a potential agent for the passive immunotherapy of cancer, particularly epithelial tumors affecting breast, colon, gastric and pancreatic tissues. A phase I/II trial of IGN-311 was initiated in July 2005.
MeSH terms
-
Animals
-
Antibodies, Monoclonal*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / metabolism
-
Humans
-
Lewis Blood Group Antigens / immunology*
-
Neoplasms, Glandular and Epithelial / drug therapy*
-
Neoplasms, Glandular and Epithelial / immunology
-
Neoplasms, Glandular and Epithelial / metabolism
-
Signal Transduction / drug effects
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
IGN 311
-
Lewis Blood Group Antigens
-
Lewis Y antigen
-
ErbB Receptors